On 28 June 2019, orphan designation EU/3/19/2173 was granted by the European Commission to Myelo Therapeutics GmbH, Germany, for imidazolyl ethanamide pentandioic acid (also known as Myelo001) for the treatment of acute radiation syndrome.
The sponsor’s address was updated in April 2020.
Imidazolyl ethanamide pentandioic acid
|Disease / condition||
Treatment of acute radiation syndrome
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.